Latest news with #CommercialCode
Yahoo
3 days ago
- Business
- Yahoo
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMF PARIS, June 05, 2025--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth ParisISIN code: FR0010609263, Ticker: ALMKTWebsite: Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) May 31, 2025 74,989,997 76,077,471 76,077,471 Including 1,200,000 new shares issued during the month as part of the equity financing facility (see press releases published on July 25, 2024 and April 24, 2025). (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. (2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007. *** About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit View source version on Contacts Mauna Kea Technologies investors@ NewCap - Investor Relations Aurélie Manavarere / Thomas Grojean+33 (0)1 44 71 94 94maunakea@
Yahoo
14-05-2025
- Business
- Yahoo
The results of the voluntary takeover offer made by Eesti Energia AS in respect of the shares of Enefit Green AS
On 7 April 2025, a shareholder of Enefit Green AS, Eesti Energia AS (registry code: 10421629, 'Offeror'), notified of making a voluntary takeover offer to acquire all shares of Enefit Green AS not in the ownership of the Offeror. Today, on 14 May 2025, the Offeror published the results of the voluntary takeover offer. Below we publish the Offeror's notice regarding the results of the voluntary takeover offer as it was originally made by the results of the voluntary takeover offer made in respect of the shares of Enefit Green AS Eesti Energia AS ('Offeror') made a voluntary takeover offer to all the shareholders of Enefit Green AS ('Enefit Green') for acquiring all the shares of Enefit Green ('Shares') not yet in the ownership of the Offeror ('Offer'). The Offer was made based on the offer notice ('Offer Notice') and the prospectus attached to it ('Prospectus', together with the Offer Notice, 'Offer Documents'). The Estonian Financial Supervision and Resolution Authority approved the Offer on 7 April 2025 and the Offer Documents were published on 7 April 2025. The Offer commenced on 8 April 2025 at 10:00 and ended on 12 May 2025 at 16:00. The purchase price offered by the Offeror within the Offer was EUR 3.40 per one Share (the 'Purchase Price'). As a response to the Offer the shareholders participating in the Offer decided to sell to the Offeror in total 52,940,905 Shares that corresponds to approximately 20% of all the Shares. The Offeror gives its acceptance to conclude the sales contracts with all the shareholders that participated in the Offer on terms provided in the Prospectus. The payment of the Purchase Price to all the shareholders participating in the Offer and transfer of the Shares to the Offeror takes place on 16 May 2025 (the 'Value Date') in accordance with the procedure described in the Offer Documents. On the Value Date each shareholder participating in the Offer shall be paid the amount of the Purchase Price corresponding to the number of the Shares sold by that shareholder against the transfer of such Shares. Before publishing the Offer Documents and as of the end of the last day of Offer the Offeror held in total 203,931,405 Shares that amounted to 77.17% of all Shares. As a result of the Offer, the Offeror acquires in total 52,940,905 Shares that amounts to approximately 20% of all Shares. After the Value Date, the Offeror, thus, owns in total 256,872,310 Shares that amounts to 97,2% of all Shares. Thus, the Offeror acquires as a result of the Bid a shareholding in Enefit Green due to which at least 9/10 of the voting share capital of Enefit Green is represented by Shares held by it and the Suspensive Condition described in clause 2.6 of the Prospectus has been realised and fulfilled. Accordingly, the Offeror applies for the takeover of the remaining Shares in accordance with the provisions of 1821 of the Securities Market Act and Chapter 291 of the Commercial Code. To this end, the Offeror will prepare a takeover report explaining and justifying the conditions for the transfer of the shares held by the minority shareholders and the basis for determining the amount of compensation to be paid for the shares. Following the preparation of the takeover report and their auditor's report, the Offeror will request Enefit Green to convene a meeting of the shareholders to decide on the takeover and the delisting of the Shares from Nasdaq Tallinn Stock Exchange. Prior to the shareholders' meeting, the shareholders will be given at least one month's access to the draft resolutions of the General Meeting, the annual reports of Enefit Green for the last three years, the takeover report, and the auditor's in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Adoption of Resolutions of the Extraordinary General Meeting of as Silvano Fashion Group Without Notice of the Meeting
The Management Board of AS Silvano Fashion Group, registry code 10175491, address Tulika 17, 10613, Tallinn, proposes to the shareholders to adopt resolution of the shareholders without convening a meeting pursuant to § 2991 of the Commercial Code. All questions from shareholders regarding the proposed resolutions may be sent in advance to the e-mail address info@ until May, 21 2025 and the answers to all relevant questions will be published on the website of AS Silvano Fashion Group, The list of shareholders entitled to vote on the resolution of the shareholders will be fixed on May 29, 2025, at the end of the business day of the NASDAQ CSD settlement system. Resolution of the shareholders can be voted on from May 14 to June 5, 2024 till 11:00 AM (EET). If a shareholder does not cast his or her votes, he or she shall be deemed to have voted against the resolutions. A shareholder has two options to cast his vote: 1. By sending a digitally signed or paper-signed and scanned ballot paper filled in by the voting shareholder or his / her authorized representative to the e-mail address info@ during the voting period. 2. By submitting or sending a completed ballot paper, which has been signed manually by the voting shareholder or his or her authorized representative, to the head office of AS Silvano Fashion Group at Tulika 17, 10613 Tallinn from 9:00-12:00 (EET), so that it arrives no later than June 5th, 2025, no later than 11:00 (EET). When sending paper-signed and scanned ballot papers by e-mail or when sending paper-signed ballot papers by post, a copy of the personal data page of the shareholder's or his / her representative's identity document (eg passport or ID card) must be sent together with the ballot paper. The shareholder's representative must also submit a valid power of attorney for written reproduction in Estonian or English. A shareholder may use a power of attorney form, which is available on the website of AS Silvano Fashion Group If the shareholder is a legal entity registered abroad, please send a copy of the extract from the relevant foreign commercial register showing the right of the representative to represent the shareholder (legal right of representation). The statement must be in English or translated into Estonian by a sworn translator or an official translator equivalent to a sworn translator. AGENDA: 1. Election of the auditor for auditing the economic activities of AS Silvano Fashion Group 2024. The proposals for decision of the Management Board, which have been approved by the Supervisory Board, is as follows: 1.1. To appoint the auditing company Ernst & Young Baltic AS (registry code 10877299, located at Rävala puiestee 4, 10143 Tallinn) as the auditor of AS Silvano Fashion Group; 1.2. To authorize the Management Board of AS Silvano Fashion Group to enter into an audit service agreement with the auditing company AS Ernst & Young Baltic for auditing the economic activities of AS Silvano Fashion Group 2024. The resolution adopted by the shareholders will be published as a stock exchange announcement and on the website of AS Silvano Fashion Group no later than June 6, 2025 by § 2991 (6) of the Commercial Code. AS Silvano Fashion Group Email: info@ Tel: +372 684 5000; Fax: +372 684 5300 Address: Tulika 17, 10613 Tallinn Attachments Voting ballot Power of Attorney
Business Wire
06-05-2025
- Business
- Business Wire
Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, informs its shareholders and the financial community that the Company's Combined General Meeting will be held on Tuesday, May 27, 2025, at 2 p.m., at 1 rue Lafaurie de Monbadon, 33000 Bordeaux. The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the Bulletin des Annonces Légales Obligatoires"BALO" on April 18, 2025 (bulletin number 47). Shareholders who are unable to attend the meeting in person, may exercise their voting rights remotely, before the general meeting: either by sending a proxy to the Company, or by voting by mail, At this purpose, shareholders shall use the form available on in accordance with the procedures indicated in the notice of meeting published on April 18, 2025, in the BALO. All documents relating to this General Meeting are available on request from the Company or can be consulted on the Company's website under the heading Investors / General Meetings. In accordance with the applicable legal and regulatory provisions: any registered shareholder may, up to and including the fifth day before the general meeting, request that the Company send him the documents provided for in Articles L. 225-115 and R. 225-83 of the Commercial Code. In the event of an express request, such documents may be sent by electronic means. For holders of bearer shares, the exercise of this right is subject to the provision by their authorized intermediary of a certificate of account registration; any shareholder may consult the documents referred to in Articles L. 225-115 and R. 225-83 of the Commercial Code at the company's registered office. Shareholders wishing to follow the meeting but unable to attend in person are invited to connect via the following link: click here. This live webcast will only be in French and will not allow remote voting or questions. A recording of the Meeting will be available on the Company's website ( no later than seven (7) business days after the date of the Meeting. *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS B Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document approved by the Autorité des Marchés Financiers on April 28, 2025, under number D.25-0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
23-04-2025
- Business
- Yahoo
GenSight Biologics Annual General Meeting on May 13, 2025
Procedures for obtaining preparatory documents for the General Meeting PARIS, April 23, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 13, 2025, at 2:00 pm CEST at the Company's headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast live for shareholders on at the following link: The notice containing the agenda and draft resolutions was published in the French BALO on April 7, 2025. The notice confirming the time and place of the meeting was published in the French BALO and in a legal gazette on April 23, 2025. The preparatory documents for the General Meeting listed in Article R. 22-10-23 of the French Commercial Code are posted on the Company's website ( in the Investors, Documentation section. The preparatory documents for the General Meeting will also be made available to shareholders as of the convening of the meeting. It is specified that the full text of the documents intended to be presented to the Meeting, in accordance in particular with Articles L. 225-115 and R. 225-83 of the Commercial Code, are made available at the Company's headquarters. From the date of the convocation and until the fifth day inclusive before the meeting, any shareholder may ask the Company to send him the documents and information mentioned in Articles R. 225-81 and R. 225-83 of the Commercial Code, preferably by email to the following address: investor_relations@ Bearer shareholders must justify this status by sending an account registration certificate. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. View source version on Contacts GenSight Biologics Chief Financial OfficerJan Eryk Umiastowskijeumiastowski@ Sign in to access your portfolio
